← All trials
NCT05240950
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 25, 2022
- Primary completion
- Dec 25, 2023
- Completion date
- Dec 25, 2026
- First posted
- Feb 15, 2022
- Last posted
- Mar 11, 2022
- Enrollment
- 18
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Changhai HospitalLead sponsor
- Changhai HospitalReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.